Brivanib Alaninate

Brivanib alaninate is a carboxylic ester resulting from the formal condensation of the carboxy group of L-alanine with the hydroxy group of brivanib. It is a prodrug of brivanib (BMS-540215), a potent oral dual inhibitor of VEGFR-2 and FGFR-1 (IC50 of 25 nM and 148 nM, respectively) and was in development for the treatment of hepatocellular and colon carcinomas. It has a role as an antineoplastic agent, an angiogenesis inhibitor, a prodrug, an EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor, a fibroblast growth factor receptor antagonist and an apoptosis inducer. It is a fluoroindole, a carboxylic ester, an aromatic ether, a diether, a L-alanine derivative and a pyrrolotriazine. It is functionally related to a brivanib.

Disclaimer: The information above is provided for general reference purposes only. Applications, dosage, handling procedures and suitability for any specific use must be determined solely by the user based on their own assessment. This information does not constitute a recommendation or endorsement for any particular application and should not be used as the basis for product selection.